Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
j0jjFKRJnRYdaCyU
Listen
